Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
FLUVASTATIN SODIUM
Clonmel Healthcare Ltd
80 Milligram
Tablet Prolonged Release
2008-12-12
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lochol XL 80 mg prolonged-release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 80 mg fluvastatin (as fluvastatin sodium). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged-release tablet Yellow, round, biconvex tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dyslipidaemia Treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Secondary prevention in coronary heart disease Secondary prevention of major adverse cardiac events in adults with coronary heart disease after percutaneous coronary interventions (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults_ Dyslipidaemia Prior to initiating treatment with Lochol XL 80 mg prolonged-release tablets, patients should be placed on a standard cholesterol-lowering diet, which should be continued during treatment. Starting and maintenance doses should be individualized according to the baseline LDL-C levels and the treatment goal to be accomplished. Lochol XL 80 mg prolonged release tablets are NOT suitable for treatment initiation, for this purpose alternative pharmaceutical forms and tablet strengths (20 mg and 40 mg) are appropriate. The recommended dosing range is 20 to 80 mg/day. For patients requiring LDL-C reduction to a goal of <25% a starting dose of 20 mg fluvastatin may be used as a single dose in the evening. For patients requiring LDL-C reduction to a goal of ≥25%, the recommended starting dose is 40 mg fluvastatin in the evening. The dose may be uptitrated to 80 mg daily, administered as a single dose (one Perskaitykite visą dokumentą